Genenta Science Regains Nasdaq Compliance, Resolving Delisting Threat
GNTA has more than doubled off its 52-week low of $0.55 on light trading volume (0.2× avg).
Summary
Genenta Science S.p.A. announced it has regained compliance with Nasdaq's minimum bid price requirement, effectively resolving the delisting threat previously disclosed.
Key Events · Corporate Governance and Compliance · GNTA
-
Regained Nasdaq Compliance
Genenta Science S.p.A. received notification from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
-
Resolved Prior Deficiency
This action resolves the deficiency letter issued on April 14, 2026, which had notified the company of non-compliance due to its stock trading below $1.00 for 30 consecutive business days.
-
Sustained Bid Price
Nasdaq confirmed compliance after the company's American Depositary Shares (ADSs) maintained a closing bid price at or above $1.00 per share for 10 consecutive business days, from June 1 to June 12, 2026.
Analysis · GNTA · Life Sciences
This filing is important because it confirms Genenta Science has resolved the Nasdaq minimum bid price deficiency, removing the immediate threat of delisting. The company had previously received a deficiency letter on April 14, 2026, making this a critical positive development for investor confidence and the company's ability to remain publicly traded on Nasdaq.
At the time of this filing, GNTA was trading at $1.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.2M. The 52-week trading range was $0.55 to $10.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.